Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesTakeda Pharmaceutical Co Ltd ADR

Takeda Pharmaceutical Co Ltd ADR

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
21.385 USD 0.33 ( 1.54%)
Last update at 2026-11-05T18:00:00Z
VOLUME
2003944
Market Cap
59718.51M

Momentum Score

…

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate/Adynovi, Livtencity, ADZYNMA, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Flexbumin, Adcetris, Leuplin/Enantone, Ninlaro, Iclusig, FRUZAQLA, Alunbrig, vyvanse/elvanse, Trintellix, and QDENGA brands. It has licensing and collaboration for the development and commercialization of products with Arrowhead Pharmaceuticals, Cour Pharmaceuticals, Engitix, Halozyme, Mirum Pharmaceuticals, Ucsd/Fortis Advisors, Zedira/Dr. Falk Pharma, Ac Immune, Acurastem, Anima Biotech, Biomarin, Denali Therapeutics, Luxna Biotech, Neurocrine Biosciences, Peptidream, Abbvie, Adimab, Ascentage Pharma, Crescendo Biologics, Exelixis, F-Star, Gsk, Heidelberg Pharma, Innovent Biologics, Keros Therapeutics, Kumquat Biosciences, Protagonist Therapeutics, Halozyme, Kamada, Johnson & Johnson/Momenta Pharmaceuticals, Previpharma, Novavax, Bridgene Biosciences, Charles River Laboratories, Iambic Therapeutics, Ipsen, Km Biologics, Massachusetts Institute Of Technology, and Nabla Bio. The company operates in Japan, the United States. Europe, Canada, Latin America, China, Asia, Russia/Commonwealth of Independent States, the Middle East, Oceania, and Africa. The company was founded in 1781 and is headquartered in Chuo, Japan.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
21.34
Low
21.73
High
52 Week Price Range
12.77
Low
18.89
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
21.06
Dividend Yield
3.31%
Revenue TTM
4618934.81M
Revenue Per Share
1462.74
Gross Profit TTM
2977719.91M
Debt / Equity
0.63
ROE
-2.26%
Net Debt
4305376.50M
ROCE
5.01%
Diluted EPS TTM
-0.35

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Income before tax 275880.44M 175084.00M 52791.00M 375090.00M 302571.00M
Minority interest -264.00M -215.00M -130.00M -21.00M -107.00M
Net income 203326.75M 107928.00M 144067.00M 317017.00M 230059.00M
Selling general administrative 1084215.00M 1104766.00M 1053819.00M 997309.00M 886361.00M
Gross profit 2439331.51M 3001334.00M 2832257.00M 2783406.00M 2462160.00M
Reconciled depreciation 721127.00M 761396.00M 728002.00M 664400.00M 583151.00M
Ebit 655016.83M 449116.00M 499475.00M 490505.00M 460844.00M
Ebitda 1419633.45M 1210512.00M 1143936.00M 1209188.00M 1052329.00M
Depreciation and amortization 764616.62M 761396.00M 644461.00M 718683.00M 591485.00M
Operating income 573042.31M 342586.00M 214075.00M 490505.00M 460844.00M
Other operating expenses 4204407.95M 4238965.00M 4049687.00M 3536972.00M 3108161.00M
Interest expense 379136.40M 137311.00M 1062.44M 169698.00M 166607.00M
Tax provision 9770.00M 66941.00M -91406.00M 58052.00M 72405.00M
Interest income 16878.00M 181973.00M 11293.00M 62913.00M 23700.00M
Net interest income -143774.00M -160554.00M -140463.00M -106785.00M -142907.00M
Income tax expense 72273.76M 66941.00M -91406.00M 58052.00M 72405.00M
Total revenue 4777450.27M 4581551.00M 4263762.00M 4027478.00M 3569006.00M
Total operating expenses 1866289.19M 2658748.00M 2618182.00M 2292900.00M 2001315.00M
Cost of revenue 2338118.76M 1580217.00M 1431505.00M 1244072.00M 1106846.00M
Total other income expense net -297161.88M -167502.00M -161284.00M -115415.00M -158273.00M
Net income from continuing ops -152125.00M 108143.00M 144197.00M 317038.00M 230166.00M
Net income applicable to common shares - 107928.00M 144067.00M 317017.00M 230059.00M
Breakdown 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Total assets 15520135.74M 14248344.00M 15108792.00M 13957750.00M 13178018.00M
Intangible assets 3434178.29M 3631560.00M 4274682.00M 4269657.00M 3818544.00M
Other current assets 223445.94M 173000.00M 178212.00M 160867.00M 141098.00M
Total liab 7711616.13M 7312365.00M 7834787.00M 7603079.00M 7494495.00M
Total stockholder equity 7807307.37M 6935084.00M 7273264.00M 6354122.00M 5683019.00M
Other current liab 1432212.92M 1649132.00M 1515991.00M 1493107.00M 1425440.00M
Common stock 1702629.70M 1694685.00M 1676596.00M 1676345.00M 1676263.00M
Capital stock 1695277.00M 1694685.00M 1676596.00M 1676345.00M 1676263.00M
Retained earnings 1061114.36M 1187586.00M 1391203.00M 1541146.00M 1479716.00M
Other liab - - - 544129.00M 1207347.00M
Good will 5834204.65M 5324430.00M 5410067.00M 4790723.00M 4407749.00M
Other assets - 441027.00M -2.00M 429328.00M 678704.00M
Cash 597634.85M 385113.00M 457800.00M 533530.00M 849695.00M
Cash and equivalents - 233742.00M 205189.00M 533530.00M 389058.00M
Total current liabilities 2440067.28M 2506521.00M 2313103.00M 2481940.00M 2145730.00M
Current deferred revenue - - 109906.00M - -
Net debt 4305376.50M 4130152.00M 4385952.00M 3848811.00M 3495716.00M
Short term debt 514378.31M 548939.00M 367251.00M 339600.00M 203993.00M
Short long term debt 512157.00M 548939.00M 367251.00M 339600.00M 203993.00M
Short long term debt total 4903011.35M 4515265.00M 4843752.00M 4382341.00M 4345411.00M
Other stockholder equity 1734715.26M 1700898.00M 1696155.00M 3136631.00M 2527040.00M
Property plant equipment - 1968209.00M 1989777.00M 1691229.00M 1582800.00M
Total current assets 3103907.03M 2521192.00M 2558580.00M 2397956.00M 2593642.00M
Long term investments 448737.00M 361926.00M 430608.00M 378857.00M 330133.00M
Net tangible assets - - - - -2543274.00M
Short term investments 41888.00M 20476.00M 15089.00M 20174.00M 25305.00M
Net receivables 880148.87M 725254.00M 697610.00M 681693.00M 724377.00M
Long term debt 4369681.00M 3966326.00M 4476501.00M 4042741.00M 4141418.00M
Inventory 1402677.38M 1217349.00M 1209869.00M 986457.00M 853167.00M
Accounts payable 493476.05M 308450.00M 319955.00M 649233.00M 516297.00M
Accumulated other comprehensive income 3308848.06M 2351915.00M 2509310.00M - -
Non currrent assets other 77343.00M 70282.00M 51214.00M 63325.00M 82611.00M
Non current assets total 12416228.71M 11727152.00M 12550214.00M 11559794.00M 10584376.00M
Long term debt total - 3966326.00M 4476501.00M 4042741.00M 4141418.00M
Breakdown 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Investments -10400.00M -367060.00M -463862.00M -607102.00M -198125.00M
Change to liabilities - - - 0.00M 125157.00M
Total cashflows from investing activities -369141.00M -367060.00M -463862.00M -607102.00M -198125.00M
Net borrowings 1076.00M -314314.00M 1513.00M -285071.00M -600477.00M
Total cash from financing activities -496820.00M -751425.00M -354416.00M -709148.00M -1070265.00M
Change to operating activities - - - 63568.00M -66289.00M
Net income -152125.00M 108143.00M 144197.00M 317038.00M 230166.00M
Change in cash 209941.00M -72687.00M -75730.00M -316165.00M -116527.00M
Begin period cash flow 385113.00M 457800.00M 533530.00M 849695.00M 966222.00M
End period cash flow 595054.00M 385113.00M 457800.00M 533530.00M 849695.00M
Total cash from operating activities 1041431.00M 1057182.00M 716344.00M 977156.00M 1123105.00M
Depreciation 721127.00M 761396.00M 728002.00M 664400.00M 583151.00M
Other cashflows from investing activities -216320.00M -161567.00M -276356.00M 26587.00M -1007.00M
Dividends paid 311901.00M 302498.00M 287188.00M -279416.00M -283665.00M
Change to inventory -61293.00M -34973.00M -115743.00M -79155.00M -46148.00M
Change to account receivables -70166.00M -58959.00M 15104.00M - 127294.00M
Sale purchase of stock -51603.00M -51860.00M -2326.00M -26929.00M -77531.00M
Other cashflows from financing activities -134392.00M -82753.00M -66415.00M -2732.00M 140742.00M
Change to netincome - - - 21003.00M 169881.00M
Capital expenditures 414659.00M 379625.00M 480730.00M 633689.00M 186037.00M
Change in working capital 199905.00M -59372.00M -256003.00M -25264.00M 98605.00M
Stock based compensation 72775.00M 72867.00M 70871.00M 60672.00M 43374.00M
Other non cash items 189979.00M 107207.00M 120683.00M -97742.00M 95404.00M
Free cash flow 626772.00M 677557.00M 235614.00M 343467.00M 937068.00M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
TAK
Takeda Pharmaceutical Co Ltd ADR		 0.33
1.54%		 21.39 - 10.96 0.01 1.20 2.94 23.11
MKKGY
Merck KGaA ADR		 -0.44
1.29%		 33.62 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 -2.43
1.43%		 167.57 24.86 15.11 3.13 1.98 3.08 18.89
TKPHF
Takeda Pharmaceutical Co. Ltd.		 0.01
0.01%		 41.85 - 10.66 0.01 1.16 2.94 23.11
TEVA
Teva Pharma Industries Ltd ADR		 -0.28
0.66%		 41.58 65.42 12.55 2.64 5.82 3.35 18.43

Profile*

Takeda Pharmaceutical Co Ltd ADR

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate/Adynovi, Livtencity, ADZYNMA, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Flexbumin, Adcetris, Leuplin/Enantone, Ninlaro, Iclusig, FRUZAQLA, Alunbrig, vyvanse/elvanse, Trintellix, and QDENGA brands. It has licensing and collaboration for the development and commercialization of products with Arrowhead Pharmaceuticals, Cour Pharmaceuticals, Engitix, Halozyme, Mirum Pharmaceuticals, Ucsd/Fortis Advisors, Zedira/Dr. Falk Pharma, Ac Immune, Acurastem, Anima Biotech, Biomarin, Denali Therapeutics, Luxna Biotech, Neurocrine Biosciences, Peptidream, Abbvie, Adimab, Ascentage Pharma, Crescendo Biologics, Exelixis, F-Star, Gsk, Heidelberg Pharma, Innovent Biologics, Keros Therapeutics, Kumquat Biosciences, Protagonist Therapeutics, Halozyme, Kamada, Johnson & Johnson/Momenta Pharmaceuticals, Previpharma, Novavax, Bridgene Biosciences, Charles River Laboratories, Iambic Therapeutics, Ipsen, Km Biologics, Massachusetts Institute Of Technology, and Nabla Bio. The company operates in Japan, the United States. Europe, Canada, Latin America, China, Asia, Russia/Commonwealth of Independent States, the Middle East, Oceania, and Africa. The company was founded in 1781 and is headquartered in Chuo, Japan.

1-1, Nihonbashi-Honcho 2-chome, Chuo, Japan, 103-8668

81 3 3278 2111

https://www.takeda.com

47029

Name Title Year Born
Mr. Christophe Weber Pres, CEO & Representative Director 1966
Mr. Constantine Saroukos CFO & Representative Director 1971
Dr. Andrew S. Plump Pres of R&D and Representative Director 1965
Dr. Seigo Izumo Chair of Management Board NA
Mr. Haruhiko Hirate Member of Management Board 1957
Salvatore Alesci Member of Management Board and Head of R&D Global Science & Biomedical Policy NA
Norimasa Takeda Chief Accounting Officer & Corp. Controller NA
Mr. Iwaaki Taniguchi Sr. VP of Corp. Fin. & Controlling Department NA
Mr. Gabriele Ricci Chief Data & Technology Officer 1978
Mr. Christopher David O'Reilly Global Head of Investor Relations & Global Fin. NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DHT-U
CAD 13.53
+16.44%
LIF
CAD 22.04
+8.62%
TOI
CAD 103.80
+7.09%
CRON
CAD 5.26
+6.69%
CIA
CAD 2.04
+6.25%
ITH
CAD 1.61
-34.02%
IFOS
CAD 1.65
-22.90%
TNZ
CAD 49.70
-19.58%
KEEL
CAD 2.36
-19.45%
GIL
CAD 49.36
-18.33%

Equity Sectors*

  • Basic Materials

    -2.18%

  • Communication Services

    +0.95%

  • Consumer Cyclical

    -2.25%

  • Consumer Defensive

    -0.68%

  • Energy

    -2.93%

  • Financial Services

    -2.26%

  • Healthcare

    -0.46%

  • Industrials

    -3.70%

  • Real Estate

    -0.06%

  • Technology

    -3.32%

  • Utilities

    -0.50%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…